Photo Credit: sumaki
The following is a summary of “Anti-IgE therapy in chronic rhinosinusitis with nasal polyps,” published in the November 2024 issue of Allergy and Immunology by Chhiba et al.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 (T2) inflammatory condition that impacts QoL and healthcare costs, with local IgE production driving the immune response.
Researchers conducted a prospective study to examine the role of local IgE production in CRSwNP.
They reviewed clinical trials, including the pivotal POLYP 1 and POLYP 2 studies, to assess the efficacy of omalizumab in CRSwNP. The studies measured outcomes such as nasal polyp size reduction, symptom improvement, and QoL, particularly in patients with comorbid asthma and aspirin-exacerbated respiratory disease (AERD).
The results showed that omalizumab effectively reduced nasal polyp size, improved symptom scores, and enhanced QoL, especially in patients with asthma and AERD. Its effect involves a reduction in local IgE and T2 inflammation, though the exact mechanism remains unclear.
They concluded that omalizumab was an effective and safe T2-targeted therapy for CRSwNP, with sustained benefits. Further research was needed to optimize treatment duration, identify predictive biomarkers, and compare its efficacy with other biologics like dupilumab.
Source: jacionline.org/article/S0091-6749(24)01215-6/abstract
